Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / COM
-
Number of holders
-
226
-
Total 13F shares, excl. options
-
57.1M
-
Shares change
-
-4.23M
-
Total reported value, excl. options
-
$8.64B
-
Value change
-
-$529M
-
Put/Call ratio
-
0.45
-
Number of buys
-
103
-
Number of sells
-
-201
-
Price
-
$151.17
Significant Holders of Biohaven Pharmactl Hldg Co L - COM (BHVN) as of Q3 2022
359 filings reported holding BHVN - Biohaven Pharmactl Hldg Co L - COM as of Q3 2022.
Biohaven Pharmactl Hldg Co L - COM (BHVN) has 226 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 57.1M shares
.
Largest 10 shareholders include BlackRock Inc. (4.95M shares), UBS OCONNOR LLC (3.78M shares), HBK INVESTMENTS L P (3.55M shares), STIFEL FINANCIAL CORP (3.07M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.31M shares), SOROS FUND MANAGEMENT LLC (2.27M shares), JPMORGAN CHASE & CO (2.04M shares), FARALLON CAPITAL MANAGEMENT LLC (1.95M shares), STATE STREET CORP (1.76M shares), and Capital International Investors (1.53M shares).
This table shows the top 226 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.